TI
CRSP icon

Trexquant Investment’s CRISPR Therapeutics CRSP Stock Holding History

Trexquant Investment’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.23M Sell
77,471
-49,710
-39% -$2.62M 0.02% 831
2026
Q1 		$6.05M Buy
+127,181
New +$6.71M 0.04% 573
2025
Q2 		– Sell
-38,831
Closed -$1.32M – 1577
2025
Q1 		$1.32M Buy
+38,831
New +$1.65M 0.02% 1009
2024
Q2 		– Sell
-49,787
Closed -$3.39M – 1568
2024
Q1 		$3.39M Sell
49,787
-82,598
-62% -$5.91M 0.07% 446
2023
Q4 		$8.29M Buy
+132,385
New +$7.32M 0.19% 128
2023
Q3 		– Sell
-36,113
Closed -$2.03M – 1510
2023
Q2 		$2.03M Buy
+36,113
New +$2.05M 0.05% 487
2022
Q3 		– Sell
-5,021
Closed -$305K – 1435
2022
Q2 		$305K Buy
+5,021
New +$295K 0.01% 1108
2021
Q2 		– Sell
-10,855
Closed -$1.32M – 1154
2021
Q1 		$1.32M Buy
+10,855
New +$1.64M 0.12% 220
2020
Q3 		– Sell
-6,088
Closed -$447K – 1245
2020
Q2 		$447K Sell
6,088
-41,167
-87% -$2.41M 0.03% 716
2020
Q1 		$2M Sell
47,255
-6,638
-12% -$343K 0.15% 218
2019
Q4 		$3.28M Buy
53,893
+43,529
+420% +$2.38M 0.19% 160
2019
Q3 		$425K Buy
10,364
+463
+5% +$22.1K 0.04% 505
2019
Q2 		$466K Buy
+9,901
New +$396K 0.04% 482
2019
Q1 		– Sell
-54,558
Closed -$1.56M – 1041
2018
Q4 		$1.56M Buy
54,558
+48,925
+869% +$1.7M 0.1% 314
2018
Q3 		$250K Buy
+5,633
New +$295K 0.02% 746
2018
Q2 		– Sell
-11,410
Closed -$522K – 953
2018
Q1 		$522K Sell
11,410
-6,875
-38% -$284K 0.04% 621
2017
Q4 		$429K Buy
+18,285
New +$347K 0.05% 574

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Trexquant Investment's CRSP Position: Q2 2026 in Review

Trexquant Investment reduced its CRISPR Therapeutics (CRSP) stake by 39% in Q2 2026, selling an estimated $2.62M and leaving 77,471 shares worth $4.23M. The position accounts for 0.02% of the portfolio, ranked #831.

Trexquant Investment first reported a position in CRSP in Q4 2017 and has held it in 17 quarters since. The position peaked at $8.29M in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Trexquant Investment held 77,471 shares of CRISPR Therapeutics worth $4.23M as of Q2 2026.
  • Trexquant Investment sold 49,710 CRISPR Therapeutics shares in Q2 2026, an estimated $2.62M.
  • CRISPR Therapeutics made up 0.02% of Trexquant Investment's portfolio in Q2 2026, its #831 holding.
  • Trexquant Investment first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 17 quarters since.
  • Trexquant Investment's CRISPR Therapeutics position peaked at $8.29M in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.